Study identifier:D6070C00001
ClinicalTrials.gov identifier:NCT02503774
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
Solid Tumors
Phase 1
No
-
All
190
Interventional
18 Years - 101 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2022 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Monotherapy MEDI9447 (oleclumab) only | Biological/Vaccine: MEDI9447 Subjects will receive MEDI9447 until disease progression |
Experimental: Combination MEDI9447 (oleclumab) and MEDI4736 (durvalumab) | Biological/Vaccine: MEDI9447 and MEDI4736 Subjects will receive MEDI9447 and MEDI4736 until disease progression |